Naslov
ENADA/NADH improves cognitive impairment of Alzheimer patients

Autori
Demarin, Vida ; Podobnik-Šarkanji, Slava ; Štorga-Tomić, D., Kay, K.K. ; Birkmayer, G.D.

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
First International Conference of Mechanisms of Action of Neutraceuticals / Husnjak, K ; Pavelić, J ; Pavelić, K - Zagreb : Institut Ruđer Bošković, 2001, 22-23

Skup
First International Conference of Mechanisms of Action of Neutraceuticals

Mjesto i datum
Cavtat, Hrvatska, 14.10.2001. - 19.10.2001

Vrsta sudjelovanja
Predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
ENADA; Alzheimer disease; cognitive impairment

Sažetak
The known biochemical effect of NADH and results of prior studies let us to assume that NADH would slow the progressive deterioration and possibly improve the cognitive functioning of Alzheimer's disease (AD) patients. In previous clinical trials NADH has been shown to improve cognitive functioning in patients with Parkinson's Disease Chronic Fatigue Syndrome and AD. The primary mechanism by which NADH improves cognitive functioning has yet to be determined. This was a double-blind, placebo-controlled, parallel group pilot study in which each subject (n = 48) made eight clinic visits over a period of six months. Subjects underwent a neurological examination, laboratory testing and baseline neuropsychological testing. Subjects were pair matched on the basis of initial severity of dementia, using the Mini Mental State Examination Scale and age, were randomly assigned to receive either ENADA/NADH (2 ENADA/NADH 5 mg tablets per day)or matching Placebo tablets and monitored at monthly intervals. Neuropsychological test battery consisted of the following measures: Mini Mental State Examination (MMSE) ; Mattis Dementia Rating Scale (MDRS) ; Hopkins Verbal learning Test (HVLT) ; Verbal Fluency Test (VF) ; Fuld Object Memory Test (FOMT), and CogScreenTM Matching to Sample Test (MTS). Fourtyseven AD finished the six month study period. NADH improved Verbal Fluency (p = 0.056) from baseline to six month compared to placebo. On the Fluency Test NADH subjects had an average increase of 3.5 words compared to a drop of 0.5 words for placebo subjects over the six month study period. Results for the HVLT did not show a significant advantage for NADH. However, evaluating the MDRS show NADH subjects improving by 2.8 points and placebo subjects deteriorating by 4.9 points. Furthermore, on the MDRS 15 out of 21 pairs improved on ENADA/ NADH when compared to placebo. AD patients receiving ENADA/NADH showed significant improvement on measures of the MDRS and VF. For patients receiving NADH not only was there a suspension of cognitive deterioration but for several subjects there was a clinical improvement in cognitive functioning. Importantly ENADA/NADH is a natural biological hence very safe substance (nutritional supplement) and was not associated with adverse or side effects.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA